HAVCR2 and neoplasm: Further exploration of treatments targeting other immune checkpoints, including LAG-3, VISTA, TIGIT, TIM-3, ADORA2, as well as therapies involving TIL (tumor-infiltrating lymphocytes), holds promise for delivering survival benefits to this subgroup of patients.